Bio-Path reports FY2022 net loss of $13.9M ($1.91/share); cash drops to $10.4M

BIO-PATH HOLDINGS, INC.

2023-Q1 EPS reported -$0.66

Net loss $13.9M ($1.91 per share) vs $10.4M ($1.55) in 2021; R&D expense rose to $9.2M.
Cash at Dec 31, 2022 was $10.4M, down from $23.8M; operating cash burn of $15.1M.
First patient dosed in Phase 1/1b trial of BP1001-A in solid tumors (ovarian, pancreatic, breast).
Phase 2 prexigebersen AML trial: two cohorts exceeded minimum efficacy; interim analyses expected Q2 2023.
BP1002 Phase 1/1b in relapsed/refractory AML: initial cohort data readout expected Q2 2023.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 1.0

BIO-PATH HOLDINGS, INC. reported the year ended December 31, 2022 results: net income a net loss of $13.9 million, or $1.91 per share.

Period: the year ended December 31, 2022
Net income: a net loss of $13.9 million, or $1.91 per share
Result: reported results

Exact text from the filing

The Company reported a net loss of $13.9 million, or $1.91 per share, for the year ended December 31, 2022

View on SEC.gov

51 earnings releases filed in the last 30 days. Browse all earnings releases →

BIO-PATH HOLDINGS, INC. filing history →

Source: SEC EDGAR

accession 0001558370-23-005188

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.